Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing Centralized Hospital Safety Surveillance of Shuxuening Injection (Xue Le Tong)
ChiCTR2000035003Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Chinese Medicine
- Start
- Sep 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of shuxuening in adverse drug reaction (ADR) and adverse drug event (ADE), sponsored by First Affiliated Hospital of Henan University of Chinese Medicine. Primary endpoint: ADR/ADE incidence and characterization. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
shuxuening
03
Conditions
adverse drug reaction (ADR)adverse drug event (ADE)
Beyond the preview
Go deeper on ChiCTR2000035003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035003.